Rubius therapeutics, inc. (RUBY)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
Cash flows from operating activities:
Net loss

-48,486

-44,472

-47,015

-39,390

-32,581

-27,183

-26,362

-21,239

-14,411

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

8,488

10,831

10,358

10,604

9,478

9,126

9,887

5,902

2,613

Depreciation and amortization expense

1,789

701

848

785

661

384

377

275

227

Change in fair value of preferred stock warrant liability

-

-

-

-

-

0

426

1,718

43

Accretion of discount on investments

29

381

724

726

489

131

78

71

49

Non-cash interest expense

87

88

87

93

21

60

5

8

13

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

-914

-4,784

987

3,837

-2,695

6,245

2,527

127

138

Operating lease, right-of-use-asset

-1,579

-1,655

-1,284

-1,543

-509

-

-

-

-

Accounts payable

905

-4,221

7,925

-3,775

-966

2,536

-631

2,581

452

Accrued expenses and other current liabilities

-3,954

2,778

1,113

5,099

-2,487

1,835

1,038

1,228

206

Deferred rent

-

-

-

-

-

-1

4

-173

155

Operating lease liabilities

-1,308

-1,259

-1,344

-354

287

-

-

-

-

Net cash used in operating activities

-40,015

-28,985

-28,748

-29,839

-22,872

-19,693

-17,861

-9,898

-10,889

Cash flows from investing activities:
Purchases of property, plant and equipment

2,851

13,276

9,966

13,251

4,164

3,281

10,213

628

830

Purchases of investments

10,001

59,902

82,332

58,916

117,983

73,603

8,944

22,277

56,148

Sales and maturities of investments

105,000

83,880

89,101

25,019

29,155

-

-

-

-

Net cash provided by (used in) investing activities

92,148

10,702

-3,197

-47,148

-92,992

-46,059

593

-9,195

-56,978

Cash flows from financing activities:
Proceeds from issuance of convertible preferred stock, net of issuance costs

-

-

-

-

-

0

0

0

100,986

Proceeds from issuance of common stock upon exercise of stock options

486

570

472

572

799

46

0

14

4

Net cash provided by financing activities

486

570

350

25,572

799

19,163

255,132

-456

100,990

Net increase (decrease) in cash, cash equivalents and restricted cash

52,619

-17,713

-31,595

-51,415

-115,065

-46,589

237,864

-19,549

33,123

Supplemental cash flow information:
Cash paid for interest, net of interest capitalized

895

1,255

673

697

336

-

-

-

79

Cash paid for leases

2,147

2,181

2,110

907

177

-

-

-

-

Supplemental disclosure of non-cash investing and financing information:
Lease assets obtained in exchange for new operating lease liabilities

-

303

21,552

0

27,944

-

-

-

-

Lease asset derecognized upon lease cancellation

982

-

-

-

-

-

-

-

-

Purchases of property, plant and equipment included in accounts payable or accrued expenses

923

-2,978

1,334

109

4,630

197

503

627

223

Amounts capitalized under build-to-suit lease transaction

-

-

-

-

-

-

7,739

5,899

11,019